Definition of Patients Presenting a High Risk of Developing Peritoneal Carcinomatosis After Curative Surgery for Colorectal Cancer: A Systematic Review

Honoré, Charles; Goèré, Diane; Souadka, Amine; Dumont, Frédéric; Élias, Dominique

doi:10.1245/s10434-012-2473-5

Cited by 140 publications

(103 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A third group of patients documented to be at extreme risk of subsequent PM are patients with perforated primary colon or rectal cancer. Honore et al estimated the incidence of PM in this group of patients as 60% [2]. These three groups of patients are the focus of this manuscript.…”

Section: Patients To Be Included In This Clinical Pathwaymentioning

confidence: 92%

“…In a review, Honore et al estimated that 80% of patients would progress [2]. Equally problematic in terms of progression of peritoneal surface disease are ovarian metastases.…”

Section: Patients To Be Included In This Clinical Pathwaymentioning

confidence: 99%

“…Equally problematic in terms of progression of peritoneal surface disease are ovarian metastases. Again, Honore et al estimated an 80% of these patients would progress as PM [2]. A third group of patients documented to be at extreme risk of subsequent PM are patients with perforated primary colon or rectal cancer.…”

Section: Patients To Be Included In This Clinical Pathwaymentioning

confidence: 99%

“…Perforation will be a part of the patients' symptoms in 4% of patients. These patients taken together give a 16% incidence of PM in patients with primary colon cancer [2]. These 16% of patients may be asymptomatic or have obstruction, bleeding or perforation as a presenting symptom.…”

Section: Incidence Of Primary Colon Cancer With Peritoneal Metastasesmentioning

confidence: 99%

See 3 more Smart Citations

Management Of Unexpected Peritoneal Metastases With Primary Colorectal Cancer Using Second-Look Surgery With HIPEC

Sugarbaker¹,

Gléhen²

2017

Cancer Surg

View full text Add to dashboard Cite

Background: Peritoneal metastases (PM) will be unexpectedly present in approximately 10% of colorectal cancer patients having primary cancer resection. In the past this was considered to be an incurable condition with a terminal outcome. In patients determined to have peritoneal dissemination at the time of resection, the intervention was considered palliative. Recently, long term benefit from definitive treatment of PM with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has become a reality. These treatments are now appropriate for primary appendiceal and colorectal cancer determined to have PM at the time of resection.

show abstract

Section: Patients To Be Included In This Clinical Pathwaymentioning

confidence: 92%

“…In a review, Honore et al estimated that 80% of patients would progress [2]. Equally problematic in terms of progression of peritoneal surface disease are ovarian metastases.…”

Section: Patients To Be Included In This Clinical Pathwaymentioning

confidence: 99%

Section: Patients To Be Included In This Clinical Pathwaymentioning

confidence: 99%

Section: Incidence Of Primary Colon Cancer With Peritoneal Metastasesmentioning

confidence: 99%

See 2 more Smart Citations

Management Of Unexpected Peritoneal Metastases With Primary Colorectal Cancer Using Second-Look Surgery With HIPEC

Sugarbaker¹,

Gléhen²

2017

Cancer Surg

View full text Add to dashboard Cite

show abstract

“…The debated risk factors are: Invasion of or beyond the serosa (pT3, pT4), perforated tumors, positive peritoneal cytology (augmented by immunohistochemistry), occurrence of Krukenberg tumors and mucinous type of tumor [110] . Following a systematic review, three situations were identified to be associated with an increased frequency of metachronous PM development: Synchronous PM, ovarian metastases, and perforated tumor [111] . Despite all human and material efforts dedicated to CRSHIPEC treatment, there are patients in whom evolving disease occurs.…”

Section: Pm Multimodal Treatment -Research Pathways (2010-2014)mentioning

confidence: 99%

Multimodality treatment strategies have changed prognosis of peritoneal metastases

Lungoci

Mironiuc

Muntean

et al. 2016

WJGO

View full text Add to dashboard Cite

For a long time, treatment of peritoneal metastases (PM) was mostly palliative and thus, this status was link with "terminal status/despair". The current multimodal treatment strategy, consisting of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), has been strenuously achieved over time, but seems to be the best treatment option for PM patients. As we reviewed the literature data, we could emphasize some milestones and also, controversies in the history of proposed multimodal treatment and thus, outline the philosophy of this approach, which seems to be an unusual one indeed. Initially marked by nihilism and fear, but benefiting from a remarkable joint effort of human and material resources (multi-center and -institutional research), over a period of 30 years, CRS and HIPEC found their place in the treatment of PM. The next 4 years were dedicated to the refinement of the multimodal treatment, by launching research pathways. In selected patients, with requires training, it demonstrated a significant survival results (similar to the Hepatic Metastases treatment), with acceptable risks and costs. The main debates regarding CRS and HIPEC treatment were based on the oncologists' perspective and the small number of randomized clinical trials. It is important to statement the PM patient has the right to be informed of the existence of CRS and HIPEC, as a real treatment resource, the decision being made by multidisciplinary teams. Core tip: The multimodal treatment of peritoneal metastases (PM), involving cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, has been strenuously achieved over time, but seems to be the best treatment option, for selected cases. This paper addresses data about the multimodal treatment strategy, focused to patient's survival, the key indicator for assessing results, in the case of PM. Also, it were highlighted the treatment key aspects and the controversies, high in the 35 years of treatment implementing. By understanding the philosophy of multimodal treatment, physicians will be able to offer an alternative to the routine systemic chemotherapy.Lungoci C, Mironiuc AI, Muntean V, Oniu T, Leebmann H, Mayr M, Piso P. Multimodality treatment strategies have changed prognosis of peritoneal metastases.

show abstract

Multicentre study of laparoscopic or open assessment of the peritoneal cancer index (BIG-RENAPE)

Passot

Dumont

Goèré

et al. 2018

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

Definition of Patients Presenting a High Risk of Developing Peritoneal Carcinomatosis After Curative Surgery for Colorectal Cancer: A Systematic Review

Abstract: Evidence regarding the incidence of recurrent PC after curative surgery for colorectal cancer is poor. Emerging data indicate three situations that could result in a real higher risk of recurrent PC: synchronous PC, synchronous isolated ovarian metastases, and a perforated primary tumor.

Cited by 140 publications

References 79 publications

Management Of Unexpected Peritoneal Metastases With Primary Colorectal Cancer Using Second-Look Surgery With HIPEC

Management Of Unexpected Peritoneal Metastases With Primary Colorectal Cancer Using Second-Look Surgery With HIPEC

Multimodality treatment strategies have changed prognosis of peritoneal metastases

Multicentre study of laparoscopic or open assessment of the peritoneal cancer index (BIG-RENAPE)

Contact Info

Product

Resources

About